½ÃÀ庸°í¼­
»óǰÄÚµå
1586120

½ÉÀå ¸ÅÇÎ ½ÃÀå : À¯Çü, ÀûÀÀÁõ, ±â¼ú, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è Àü¸Á(2025-2030³â)

Cardiac Mapping Market by Type (Contact Cardiac Mapping System, Non-Contact Cardiac Mapping System), Indication (Atrial Fibrillation, Atrial Flutter, Atrioventricular Nodal Reentry Tachycardia), Technology, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÉÀå ¸ÅÇÎ ½ÃÀåÀº 2023³â¿¡ 21¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 23¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 10.55%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 42¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉÀå ¸ÅÇÎÀº ºÎÁ¤¸Æ°ú °°Àº ºñÁ¤»óÀûÀÎ ½ÉÀå ¸®µëÀÇ ±â¿ø°ú °æ·Î¸¦ ÆÄ¾ÇÇÏ´Â µ¥ »ç¿ëµÇ´Â °í±Þ Áø´Ü ÀýÂ÷ÀÔ´Ï´Ù. ½ÉÀå ¸ÅÇÎÀÇ Çʿ伺Àº Á¤È®ÇÑ Áø´Ü°ú Ä¡·á°¡ ÇÊ¿äÇÑ ½ÉÀå Áúȯ Áõ°¡¿Í Àü±â»ý¸®ÇÐÀÇ ¹ßÀü¿¡ ±âÀÎÇÕ´Ï´Ù. ½ÉÀå ¸ÅÇÎÀÇ ¿ëµµ´Â ´Ù¾çÇÑ ½ÉÀå ÁúȯÀÇ Áø´Ü°ú ºÎÁ¤¸ÆÀ» °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ÀýÁ¦¼úÀÇ Á¤È®µµ Çâ»ó µî ´Ù¾çÇÕ´Ï´Ù. ÁÖ·Î º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ½ÉÀå Àü¹®¼¾ÅÍ¿¡¼­ äÅÃÇϰí ÀÖÀ¸¸ç, 3D ¸ÅÇÎ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀü, ½ÉÇ÷°ü°è ÁúȯÀÇ ºÎ´ã Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡ µîÀÇ ¿µÇâ¿äÀÎÀÌ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ÀΰøÁö´É°ú ¿ø°Ý ½ÉÀå ¸ð´ÏÅ͸µÀÇ ÅëÇÕÀº ȯÀÚ °á°ú¿Í ¾÷¹« È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ÀáÀçÀû ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº ½Ã¼ú ºñ¿ë, ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© µîÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀÌ Á¦Çѵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹¿¡¼­´Â ÀçÁ¤Àû À庮ÀÌ ¶Ç ´Ù¸¥ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å°ú ¿¬±¸´Â ºñ¿ë È¿À²ÀûÀ̰í ÈÞ´ë °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» °³¹ßÇÏ°í ½Ã¼úÀÚ°¡ »ç¿ëÇϱ⠽¬¿î ÀÎÅÍÆäÀ̽º¸¦ °­È­ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃâ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI¿Í ¸Ó½Å·¯´×À» ¿¹Ãø ºÐ¼®¿¡ Ȱ¿ëÇϸé Áø´Ü°ú °³ÀÎÈ­µÈ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ½ÃÀåÀÇ ½Ã¾ß¸¦ ³ÐÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀåÀÇ ´Ù¾çÇÏ°í º¹ÀâÇÑ Æ¯¼ºÀ» °í·ÁÇÒ ¶§, Àü·«Àû Á¦ÈÞ¿Í ÆÄÆ®³Ê½ÊÀº ÀÚ¿ø°ú Áö½ÄÀ» °øÀ¯ÇÔÀ¸·Î½á ¼ºÀåÀ» °¡¼ÓÇϰí Çõ½ÅÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇÐÀº º»ÁúÀûÀ¸·Î ¿ªµ¿ÀûÀ̸ç, ºü¸¥ ±â¼ú ¹ßÀü°ú ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã°¡ Ư¡ÀÔ´Ï´Ù. ±â¾÷Àº °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ R&D ÅõÀÚ¸¦ Ȱ¿ëÇÏ°í µ¥ÀÌÅÍ °øÀ¯¿Í Áö¼ÓÀûÀÎ ÇнÀÀ» À§ÇÑ Å¬¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀ» ¸ð»öÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö´ÜÀ» ÅëÇØ ±â¾÷Àº ÇコÄɾî ÀÎÇÁ¶ó°¡ ºÎ»óÇϰí ÀÖ´Â ¹Ì°³Ã´ Áö¿ª ½ÃÀåÀ» °³Ã´Çϰí, ÀϹÝÀûÀÎ ¹®Á¦¸¦ ÇØ°áÇϸ鼭 ¼ºÀå ÀáÀç·ÂÀ» Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 21¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 23¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 42¾ï 6,000¸¸ ´Þ·¯
CAGR(%) 10.55%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ÉÀå ¸ÅÇÎ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

½ÉÀå ¸ÅÇÎ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ã Áõ°¡
    • ½ÉÀåÁúȯÀÇ Á¶±â Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÎ½Ä Á¦°í
    • 3D Å׸¶ äÅà Ȯ´ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÉÀå ¸ÅÇÎ ½Ã¼ú ¹× Á¦Ç°°ú °ü·ÃµÈ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • ½ÉÀå ¸ÅÇÎ ±â¼úÀÇ ¹ßÀü
    • »õ·Î¿î ½ÉÀå ¸ÅÇÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ½ÂÀÎ Áõ°¡
  • ½ÃÀå °úÁ¦
    • ½ÉÀå ¸ÅÇÎ ¼Ö·ç¼ÇÀÇ ÇѰè¿Í ÀÎ½Ä ºÎÁ·

Portre's Five Forces: ½ÉÀå ¸ÅÇÎ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÉÀå ¸ÅÇÎ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½ÉÀå ¸ÅÇÎ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½ÉÀå ¸ÅÇÎ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ½ÉÀå ¸ÅÇÎ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

½ÉÀå ¸ÅÇÎ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½ÉÀå ¸ÅÇÎ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½ÉÀå ¸ÅÇÎ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ½ÉÀå ¸ÅÇÎ ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸®±â À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

½ÉÀå ¸ÅÇÎ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½ÉÀå ¸ÅÇÎ ½ÃÀå : À¯Çüº°

  • Contact Cardiac Mapping System
    • Basket Catheter Mapping System
    • Electroanatomical Mapping System
    • Traditional Endocardial Catheter Mapping System
  • ºñÁ¢ÃËÇü ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛ

Á¦7Àå ½ÉÀå ¸ÅÇÎ ½ÃÀå : ÀûÀÀÁõº°

  • ½É¹æ¼¼µ¿
  • ½É¹æÁ¶µ¿
  • . Atrioventricular Nodal Reentry Tachycardia

Á¦8Àå ½ÉÀå ¸ÅÇÎ ½ÃÀå : ±â¼úº°

  • ½ÉÀå ¹æ»ç¼º ÇÙÁ¾ À̹Ì¡
  • Àڱ⠳»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ
  • ¿ø°Ý ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ
  • ·Îº¿ ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ

Á¦9Àå ½ÉÀå ¸ÅÇÎ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Áø´Ü¼¾ÅÍ
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ½ÉÀå ¸ÅÇÎ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ¸ÅÇÎ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÉÀå ¸ÅÇÎ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Acutus Medical
  • AngioDynamics, Inc.
  • APN Health, LLC
  • APT Medical Inc.
  • Biosense Webster, Inc.
  • Biosig Technologies, Inc.
  • BIOTRONIK SE & Co KG
  • Boston Scientific Corporation
  • Catheter Precision, Inc. by Ra Medical Systems, Inc.
  • CoreMap Inc.
  • EP Solutions SA
  • EPMap-System GmbH
  • Johnson & Johnson Services, Inc.
  • Kardium Inc.
  • Koninklijke Philips N.V.
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • Medtronic, Inc.
  • Microport Scientific Corporation
  • Siemens AG
LSH.

The Cardiac Mapping Market was valued at USD 2.11 billion in 2023, expected to reach USD 2.33 billion in 2024, and is projected to grow at a CAGR of 10.55%, to USD 4.26 billion by 2030.

Cardiac mapping is a sophisticated diagnostic procedure used to identify the origin and pathway of abnormal heart rhythms, such as those found in arrhythmias. Its necessity springs from the increasing prevalence of cardiac disorders and advancements in electrophysiology, which demand precise diagnosis and treatment. The application of cardiac mapping extends across diagnosing various heart conditions and improving the accuracy of ablation procedures, which are crucial for correcting arrhythmias. It's predominantly employed in hospitals, ambulatory surgery centers, and specialized cardiac centers. Influencing factors such as technological advancements in 3D mapping systems, the growing burden of cardiovascular diseases, and an increasing aging population drive the market upward. Furthermore, the integration of artificial intelligence and remote cardiac monitoring presents potential opportunities for enhanced patient outcomes and operational efficiency. However, the market growth is limited by high costs of procedure, lack of skilled professionals, and stringent regulatory frameworks. Furthermore, financial barriers in emerging economies pose additional challenges. Innovation and research can focus on developing cost-effective, portable cardiac mapping solutions and enhancing user-friendly interfaces for practitioners. Additionally, harnessing AI and machine learning for predictive analytics can revolutionize diagnostics and personalized therapy, broadening the market horizon. Given the diverse yet complex nature of this market, strategic alliances and partnerships can catalyze growth by pooling resources and knowledge, accelerating innovation. The nature of the cardiac mapping market is inherently dynamic, characterized by rapid technological evolution and regulatory scrutiny. Companies should capitalize on R&D investment and explore cloud-based platforms for data sharing and continued learning to stay competitive. By aligning with these avenues, firms can tap into untapped regional markets where healthcare infrastructure is on the rise, thereby leveraging growth potential while countering prevalent challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.11 billion
Estimated Year [2024] USD 2.33 billion
Forecast Year [2030] USD 4.26 billion
CAGR (%) 10.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Mapping Market

The Cardiac Mapping Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of cardiovascular diseases worldwide
    • Increasing consumer awareness towards early diagnosis and treatment of cardiac diseases
    • Growing adoption of 3D cardiac mapping
  • Market Restraints
    • High costs associated with cardiac mapping procedures and products
  • Market Opportunities
    • Advancements in cardiac mapping technologies
    • Rising approvals for novel cardiac mapping solutions
  • Market Challenges
    • Limitations and lack of awareness of cardiac mapping solutions

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Mapping Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Mapping Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Mapping Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Mapping Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Mapping Market

A detailed market share analysis in the Cardiac Mapping Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Mapping Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Mapping Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Mapping Market

A strategic analysis of the Cardiac Mapping Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Mapping Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acutus Medical, AngioDynamics, Inc., APN Health, LLC, APT Medical Inc., Biosense Webster, Inc., Biosig Technologies, Inc., BIOTRONIK SE & Co KG, Boston Scientific Corporation, Catheter Precision, Inc. by Ra Medical Systems, Inc., CoreMap Inc., EP Solutions SA, EPMap-System GmbH, Johnson & Johnson Services, Inc., Kardium Inc., Koninklijke Philips N.V., Lepu Medical Technology(Beijing)Co.,Ltd., Medtronic, Inc., Microport Scientific Corporation, and Siemens AG.

Market Segmentation & Coverage

This research report categorizes the Cardiac Mapping Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Contact Cardiac Mapping System and Non-Contact Cardiac Mapping System. The Contact Cardiac Mapping System is further studied across Basket Catheter Mapping System, Electroanatomical Mapping System, and Traditional Endocardial Catheter Mapping System.
  • Based on Indication, market is studied across Atrial Fibrillation, Atrial Flutter, and Atrioventricular Nodal Reentry Tachycardia.
  • Based on Technology, market is studied across Cardiac Radionuclide Imaging, Magnetic Navigation System, Remote Navigation System, and Robotic Navigation System.
  • Based on End-User, market is studied across Ambulatory Surgical Center, Diagnosis Center, and Hospital & Clinic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of cardiovascular diseases worldwide
      • 5.1.1.2. Increasing consumer awareness towards early diagnosis and treatment of cardiac diseases
      • 5.1.1.3. Growing adoption of 3D cardiac mapping
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with cardiac mapping procedures and products
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in cardiac mapping technologies
      • 5.1.3.2. Rising approvals for novel cardiac mapping solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and lack of awareness of cardiac mapping solutions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Mapping Market, by Type

  • 6.1. Introduction
  • 6.2. Contact Cardiac Mapping System
    • 6.2.1. Basket Catheter Mapping System
    • 6.2.2. Electroanatomical Mapping System
    • 6.2.3. Traditional Endocardial Catheter Mapping System
  • 6.3. Non-Contact Cardiac Mapping System

7. Cardiac Mapping Market, by Indication

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Atrial Flutter
  • 7.4. Atrioventricular Nodal Reentry Tachycardia

8. Cardiac Mapping Market, by Technology

  • 8.1. Introduction
  • 8.2. Cardiac Radionuclide Imaging
  • 8.3. Magnetic Navigation System
  • 8.4. Remote Navigation System
  • 8.5. Robotic Navigation System

9. Cardiac Mapping Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Center
  • 9.3. Diagnosis Center
  • 9.4. Hospital & Clinic

10. Americas Cardiac Mapping Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cardiac Mapping Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cardiac Mapping Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acutus Medical
  • 3. AngioDynamics, Inc.
  • 4. APN Health, LLC
  • 5. APT Medical Inc.
  • 6. Biosense Webster, Inc.
  • 7. Biosig Technologies, Inc.
  • 8. BIOTRONIK SE & Co KG
  • 9. Boston Scientific Corporation
  • 10. Catheter Precision, Inc. by Ra Medical Systems, Inc.
  • 11. CoreMap Inc.
  • 12. EP Solutions SA
  • 13. EPMap-System GmbH
  • 14. Johnson & Johnson Services, Inc.
  • 15. Kardium Inc.
  • 16. Koninklijke Philips N.V.
  • 17. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 18. Medtronic, Inc.
  • 19. Microport Scientific Corporation
  • 20. Siemens AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦